Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures.

Eyre, Toby A; Jensen, Paw; Booth, Stephen; El-Galaly, Tarec Christoffer

Eyre, Toby A; Jensen, Paw; Booth, Stephen; El-Galaly, Tarec Christoffer.

Afiliación

Eyre TA; Department of Haematology, Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jensen P; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Booth S; Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK.
El-Galaly TC; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.

Br J Haematol ; 198(3): 431-442, 2022 08.

Article en En | MEDLINE | ID: mdl-35235226

Asunto(s)

Linfoma; Osteoporosis; Densidad Ósea; Glucocorticoides/efectos adversos; Humanos; Linfoma/tratamiento farmacológico; Osteoporosis/inducido químicamente; Osteoporosis/prevención & control; Estudios Prospectivos; Estudios Retrospectivos; Factores de Riesgo

Palabras clave

bone mineral density; fracture; glucocorticoids; late toxicity; lymphoma; osteoporosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteoporosis / Linfoma Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google